NEUROINMUNOLOGÍA
University of Calgary
Calgary, CanadáPublications en collaboration avec des chercheurs de University of Calgary (1)
2009
-
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228